TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06630156

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Revascularization of Immature Young Permenant Teeth
Description: An access cavity was prepared under rubber dam, isolation, root canal system disinfection was done without mechanical instrumentation. Subsequently, triple antibiotic paste was placed into the apical portion of the canal and filled to just below the CEJ. The access cavity was temporarily restored with glass ionomer.~4 weeks later, after reopening of the access, the antibiotic paste was gently flushed out of the canal with sterile normal saline. The root canal system was irrigated. A sterile #35 K-file will be introduced into the canal beyond the apical foramen using a push and pull motion to provoke bleeding from the periapical tissue. After bleeding control and formation of fresh blood clot, 3 mm of Bio (MTA) will be placed in Group A, 3 mm of Total Fill biocearmic root repair material will be placed in Group B after a moist cotton pellet was placed over the capping material and the access cavity will be sealed with G C

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Revascularization of Immature Young Permenant Teeth
Description: An access cavity was prepared under rubber dam, isolation, root canal system disinfection was done without mechanical instrumentation. Subsequently, triple antibiotic paste was placed into the apical portion of the canal and filled to just below the CEJ. The access cavity was temporarily restored with glass ionomer.~4 weeks later, after reopening of the access, the antibiotic paste was gently flushed out of the canal with sterile normal saline. The root canal system was irrigated. A sterile #35 K-file will be introduced into the canal beyond the apical foramen using a push and pull motion to provoke bleeding from the periapical tissue. After bleeding control and formation of fresh blood clot, 3 mm of Bio (MTA) will be placed in Group A, 3 mm of Total Fill biocearmic root repair material will be placed in Group B after a moist cotton pellet was placed over the capping material and the access cavity will be sealed with G C
Study: NCT06631534

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine 1ug/kg bolus administered over 10 minutes followed by a continuous infusion of 0.5ug/kg/hr

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline (NaCl 0,9 %) (placebo)
Description: Saline (placebo)
Study: NCT06701461

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrodermal Activity signal
Description: Determining if the electrodermal activity signals, as measured by the Embrace Plus smartwatch) can be used to measure osteoarthritic patient pain levels.
Study: NCT06747767

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arthroscopy
Description: Arthroscopy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open reduction
Description: Open reduction
Study: NCT06750263

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance exercise with clamshell
Description: balance was assessed by the Berg's Balance Scale exercise. Participants were instructed to walk (step) from one end of the mat to the other according to the step pattern provided. When reached the end of the mat, instructed to return to their starting position by walking normally off the mat and starting the next stepping. repeat every sequence five times and then started a new pattern. Duration would be 30 min. clamshell exercises a Participants were instructed to lie on their side with the weaker limb facing upwards. Both hips were flexed at 45 degrees, knees flexed at 90 degrees, and neither the feet nor the back were in contact with the wall. While keeping both heels and the first metatarsal head together, participants were instructed to separate their knees and rotate the weaker limb upward. They were advised not to tilt the limb backwards and to maintain a neutral pelvic position 3,5 sets for 10 repetations twice a week for 12 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance exercise
Description: Participants were instructed to lie on their side with the weaker limb facing upwards. Both hips were flexed at 45 degrees, the knees were flexed at 90 degrees, and neither the feet nor the back were in contact with the wall. While keeping both heels and the first metatarsal head together, participants were instructed to separate their knees and rotate the weaker limb upward. They were advised not to tilt the limb backwards and to maintain a neutral pelvic position 3,5 sets for 10 repetations twice a week for 12 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Balance exercise
Description: Participants were instructed to lie on their side with the weaker limb facing upwards. Both hips were flexed at 45 degrees, the knees were flexed at 90 degrees, and neither the feet nor the back were in contact with the wall. While keeping both heels and the first metatarsal head together, participants were instructed to separate their knees and rotate the weaker limb upward. They were advised not to tilt the limb backwards and to maintain a neutral pelvic position 3,5 sets for 10 repetations twice a week for 12 weeks
Study: NCT06749652

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: firm silicone stent insertion
Description: Insertion of firm silicon ureteral stent (Percuflex Plus)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Soft silicone ureteral stent insertion
Description: Soft silicone ureteral stent insertion
Study: NCT06751199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: human umbilical cord mesenchymal stem cells
Description: Portal vein infusion human umbilical cord mesenchymal stem cells

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: allogeneic islet
Description: Portal vein infusion of allogeneic islet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: allogeneic islet
Description: Portal vein infusion of allogeneic islet
Study: NCT06748664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rimegepant ODT 75mg , EOD treatment for 4/12* weeks
Description: All Participants will receive either Rimegepant 75 mg every other day for 4 weeks, followed by a 4-week observational phase.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, EOD treatment for 4/12* weeks
Description: All Participants will receive placebo 75 mg every other day for 4 weeks, followed by a 4-week observational phase.
Study: NCT06751017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-892216
Description: S-892216 will be administered orally as a tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Description: Carbamazepine will be administered orally as a tablet.
Study: NCT06749197

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rehacom
Description: Home-based cognitive training program

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rehacom
Description: Home-based cognitive training program
Study: NCT05729087

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Blended intervention group
Description: Face-to-face workshops will be delivered in the neighborhood elderly center every week. Each workshop will consist of two sections (a) a 60-minute PA session, including a Health talk (20 minutes), and a physical exercise training (40 minutes); and (b) a 60-minute healthy diet promotion, including group discussion and sharing (30 minutes), and knowledge of diet and nutrition (30 minutes).~In addition, a 15-minute online psychological session will be implemented following the PA and diet session.
Study: NCT04925284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XB002
Description: IV administration of XB002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XB002
Description: IV administration of XB002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XB002
Description: IV administration of XB002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XB002
Description: IV administration of XB002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: IV administration of Nivolumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: IV administration of Nivolumab
Study: NCT05648812

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Brain contrast enhanced ultrasound, brain ultrasound elastography
Description: To study brain perfusion with brain ultrasound, contrast enhanced ultrasound of the brain and ultrasound-guided shear-wave elastography

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Brain contrast enhanced ultrasound, brain ultrasound elastography
Description: To study brain perfusion with brain ultrasound, contrast enhanced ultrasound of the brain and ultrasound-guided shear-wave elastography

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Brain contrast enhanced ultrasound, brain ultrasound elastography
Description: To study brain perfusion with brain ultrasound, contrast enhanced ultrasound of the brain and ultrasound-guided shear-wave elastography

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Brain contrast enhanced ultrasound, brain ultrasound elastography
Description: To study brain perfusion with brain ultrasound, contrast enhanced ultrasound of the brain and ultrasound-guided shear-wave elastography

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfur Hexafluoride
Description: To evaluate the differences in brain perfusion studied by CEUS, comparing different patient groups and babies with no suspected brain pathology

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfur Hexafluoride
Description: To evaluate the differences in brain perfusion studied by CEUS, comparing different patient groups and babies with no suspected brain pathology

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfur Hexafluoride
Description: To evaluate the differences in brain perfusion studied by CEUS, comparing different patient groups and babies with no suspected brain pathology

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulfur Hexafluoride
Description: To evaluate the differences in brain perfusion studied by CEUS, comparing different patient groups and babies with no suspected brain pathology
Study: NCT05913687

Intervention type: DIAGNOSTIC_TEST
Intervention: AIDP
Description: Machine learning algorithm of imaging data

Intervention type: DIAGNOSTIC_TEST
Intervention: AIDP
Description: Machine learning algorithm of imaging data

Intervention type: DIAGNOSTIC_TEST
Intervention: AIDP
Description: Machine learning algorithm of imaging data
Study: NCT05673005

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MED3000 topical gel
Description: Topical gel that has been shown to improve erectile dysfunction when used as needed.
Study: NCT05682664

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Luchtbrug Junior (online monitoring)
Description: Online monitoring via Luchtbrug Junior will replace 50% of the outpatient visits. Children in the intervention group will be monitored online monthly by a digital version of TRACK.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Routine outpatient clinical visits every 3 months.
Study: NCT05626062

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Toilet alarm
Description: A Malem toilet alarm (wristworn, discretely in underwear, or bed mat) will be used to promote prompred voiding in a toilet
Study: NCT05745012

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endoscopic mucosal resection
Description: The procedure consists of performing endoscopic mucosal resection of the 3/4 of the circumference of the esogastric junction using the Duette system (Cook Endoscopy, USA). The procedure will be performed under general anesthesia in an intubated patient, and realized in ambulatory setting.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: sham
Description: The procedure consists of performing endoscopic exploration, no mucosal resection
Study: NCT05875701

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NVX-CoV2373
Description: 1 intramuscular (IM) injection of 5 µg SARS-CoV-2 rS + 50 µg Matrix-M1 adjuvant (0.5 mL) given on Day 1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 rS antigen/Matrix-M Adjuvant
Description: 1 intramuscular (IM) injection of 5 µg SARS-CoV-2 rS antigen+ 50 µg Matrix-M1 adjuvant (0.5 mL) given on Day 1
Study: NCT04842734

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical exercise
Description: SPEP are planned for 12 weeks, 2 times a week, once a day, 60 minutes / 1 hour
Study: NCT05985239

Intervention type: PROCEDURE
Intervention: VI
Description: Laparoscopic or robotic surgery with virtual ileostomy

Intervention type: PROCEDURE
Intervention: DI
Description: Laparoscopic or robotic surgery with virtual ileostomy
Study: NCT05868811

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music Together
Description: The intervention consists of 45-minute weekly classes for 16 weeks. Each class is delivered by a trained Music Together facilitator and includes music activities such as singing, dancing, moving and playing musical instruments. At the start of the program, participants receive materials for home use that consist of a song book and online access code for song recordings used in the class.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Play Group
Description: The play group consists of 45-minute weekly classes for 16 weeks. During each class parents are encouraged to play with their child and interact with other participants using the provided age appropriate toys. At the start of the program participants receive an age appropriate toy for use at home.
Study: NCT05593341

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Opioid education in person
Description: The presentation and handouts contain information regarding the following topics:~* Reviewing opioids and strategies for analgesia~  * Defining and identifying opioids~ * Goals for postoperative pain management and utilizing opioids to treat pain~ * Alternative modes of treating pain~ * Regional anesthesia/analgesia defined~* Side effects and risks of opioids~  * Common side effects of opioids~ * Risks of addiction, tolerance, dependence, opioid-induced hyperalgesia with long-term use~* Proper use and handling of opioids~  * Safe practices when taking opioids~ * Weaning off opioids~ * Safe storage and disposal of opioids

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Opioid education via video
Description: The video and handouts contain information regarding the following topics:~* Reviewing opioids and strategies for analgesia~  * Defining and identifying opioids~ * Goals for postoperative pain management and utilizing opioids to treat pain~ * Alternative modes of treating pain~ * Regional anesthesia/analgesia defined~* Side effects and risks of opioids~  * Common side effects of opioids~ * Risks of addiction, tolerance, dependence, opioid-induced hyperalgesia with long-term use~* Proper use and handling of opioids~  * Safe practices when taking opioids~ * Weaning off opioids~ * Safe storage and disposal of opioids
Study: NCT04847453

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood specimen collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration and Biopsy
Description: Undergo bone marrow aspiration and biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO
Study: NCT04842734

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical exercise and computerized cognitive training
Description: SPEP are planned for 12 weeks, 2 times a week, once a day, 60 minutes / 1 hour. The CCSP is planned for 12 weeks, minimum 3 to maximum 5 days a week, approximately 10 minutes, for a total of 36-60 sessions
Study: NCT04847453

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib Citrate
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study: NCT05049512

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multi-nut OIT
Description: Finely ground pure peanut, almond, cashew, hazelnut, and walnut.
Study: NCT04847453

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transabdominal Ultrasound
Description: Undergo transabdominal ultrasound

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: X-Ray Imaging
Description: Undergo x-ray
Study: NCT06257238

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fully immersive Head-Mounted Display Virtual Reality
Description: patients are asked to wear the Oculus Quest VR on their heads and to hold the hand controllers by their hands and start the game exercises (Dance loop, Tennis ball and Boxing) with 10 min. for each game with 1 min. rest in between, plus the traditional PT program:(Active ROM exercise for shoulder, Stretching exercise for shoulder extensors, adductors and internal rotators muscles and Strengthening exercise for shoulder muscles) 2 sessions per week for 2 months.
Study: NCT05938296

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BS006 Injection
Description: BS006 will be given every two weeks, and up to 4mL in each treatment. There will be three dose levels: 1×10\^6 CCID50/mL, 5×10\^6 CCID50/mL, 1×10\^7 CCID50/mL.
Study: NCT05633927

Intervention type: BIOLOGICAL
Intervention: SARS-CoV-2 Vaccine
Description: Analyse humoral and cellular response to SARS-CoV-2 Vaccine.

Intervention type: BIOLOGICAL
Intervention: SARS-CoV-2 Vaccine
Description: Analyse humoral and cellular response to SARS-CoV-2 Vaccine.
Study: NCT05549362

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dial Health Research Study
Description: To evaluate the feasibility and efficacy of dietary intervention approaches to slow mechanisms of aging.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dial Health Research Study
Description: To evaluate the feasibility and efficacy of dietary intervention approaches to slow mechanisms of aging.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dial Health Research Study
Description: To evaluate the feasibility and efficacy of dietary intervention approaches to slow mechanisms of aging.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dial Health Research Study
Description: To evaluate the feasibility and efficacy of dietary intervention approaches to slow mechanisms of aging.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Dial Health Research Study
Description: To evaluate the feasibility and efficacy of dietary intervention approaches to slow mechanisms of aging.
Study: NCT05634174

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirabegron
Description: Single dose, 100mg oral mirabegron

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirabegron
Description: Single dose, 100mg oral mirabegron
Study: NCT06230640

Intervention type: DIAGNOSTIC_TEST
Intervention: In vitro medical diagnostic device TEG6s® Platelet Mapping
Description: Preoperative period:~* Pre-operative blood sampling, according to the usual practices of the unit before surgery~* Collection of the patient's usual demographic characteristics~per operative period :~* After anesthetic induction:a TEG6S platelet mapping® sampled from the arterial catheter routinely placed after anesthetic induction~* During the CPB, 30 min before aortic declamping: performing TEG 6S platelet mapping® (heparinized tube)~* 5 min after heparin antagonization by protamine, after the weaning of the bypass, and before any transfusion: performing a TEG 6S citrate® (citrated tube)~Post-operative period (resuscitation):~• postoperative bleeding at 2 hours and during the first 12 hours.
Study: NCT06257238

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Physical Therapy Program
Description: patients are treated with Active ROM exercise for shoulder, Stretching exercise for shoulder extensors, adductors and internal rotators muscles and Strengthening exercise for shoulder muscles, 2 sessions per week for 2 months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Traditional Physical Therapy Program
Description: patients are treated with Active ROM exercise for shoulder, Stretching exercise for shoulder extensors, adductors and internal rotators muscles and Strengthening exercise for shoulder muscles, 2 sessions per week for 2 months.
Study: NCT05715021

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bankart + Remplissage Procedure
Description: Participants will undergo arthroscopic stabilization.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bankart + Remplissage Procedure
Description: Participants will undergo arthroscopic stabilization.
Study: NCT05743621

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TVB-2640
Description: TVB- 2640 at 100 mg, 150mg, 200 mg, 250 mg, or 300mg daily, orally; dose determined by BOIN dose escalation per the protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: 160 mg daily PO
Study: NCT04943757

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine Hydrochloride
Description: 50 mg/m2 iv Days +3 through +4 after allogeneic hematopoietic stem cell transplantation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamid
Description: 25 mg/kg iv Days +3 through +4 after allogeneic hematopoietic stem cell transplantation
Study: NCT05479812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WTX-124
Description: Investigation Product Monotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WTX-124
Description: Investigation Product Monotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WTX-124
Description: Investigation Product Monotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WTX-124
Description: Investigation Product Monotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WTX-124
Description: Investigation Product Monotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WTX-124
Description: Investigation Product Monotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WTX-124
Description: Investigation Product Monotherapy
Study: NCT05550480

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring
Description: Continuous glucose monitoring for 50 days